Article

What Should Specialty Pharmacists Know About the REVERCE Clinical Trial?

Conference|Gastrointestinal Cancers Symposium

Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.

Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Primary biliary cholangitis -- Image credit: iushakovsky | stock.adobe.com
May 20th 2025

Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
3d illustration - Bladder cancer cells - Image credit: PRB ARTS | stock.adobe.com
May 19th 2025

Anti-PD-1 Monoclonal Antibody With Standard of Care Improves Outcomes for BCG-Naïve Bladder Cancer

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Depiction of plaque build up on neurons within brain -- image credit: Dr_Microbe | stock.adobe.com
May 19th 2025

FDA Grants Market Clearance to Diagnostic Blood Test for Alzheimer Disease

Gillian McGovern, Associate Editor
NCCN Adds Naxitamab as Category 2A Recommendation for High-Risk Neuroblastoma
May 18th 2025

NCCN Adds Naxitamab as Category 2A Recommendation for High-Risk Neuroblastoma

Alana Hippensteele, Lead Editor